A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Confirm Dose Responsiveness Following 12 Weeks of the Administration of CP-690,550 (4 Doses) or Placebo in Subjects With Active Rheumatoid Arthritis Inadequately Controlled With Methotrexate Alone
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Confirm Dose Responsiveness Following 12 Weeks of the Administration of CP-690,550 (4 Doses) or Placebo in Subjects With Active Rheumatoid Arthritis Inadequately Controlled With Methotrexate Alone
The purpose of this study is to determine the effectiveness and safety, over 3 months, of 4 dose regimens of CP-690,550, combined with methotrexate, for the treatment with active rheumatoid arthritis.
Inclusion Criteria:
Exclusion Criteria:
Hitachi-shi, Ibaraki, Japan
Yahatanishi-ku, Kitakyusyu, Japan
Koushi, Kumamoto, Japan
Kawagoe-shi, Saitama, Japan
Bunkyo-ku, Tokyo, Japan
Bunkyo-k, Tokyo, Japan
Chiyoda-ku, Tokyo, Japan
Koto-ku, Tokyo, Japan
Meguro-ku, Tokyo, Japan
Musashimurayama-shi, Tokyo, Japan
Shinjyuku-ku, Tokyo, Japan